Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Intraocular Lymphoma × zanubrutinib × Lymphoid × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 30 Lymphoma, Large B-Cell, Diffuse 29 Lymphoma, Mantle-Cell 24 Waldenstrom Macroglobulinemia 18 Lymphoma, Follicular 16 Lymphoma, B-Cell, Marginal Zone 15 Recurrence 11 Lymphoma 10 Lymphoma, B-Cell 8 Lymphoma, Non-Hodgkin 6 Leukemia 4 B-cell Malignancies 3 Neoplasms 1 Multiple Myeloma 1 Mature B-Cell Malignancies 1 Lymphohistiocytosis, Hemophagocytic 1 Leukemia, B-Cell 1 Intraocular Lymphoma 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Dendritic Cell Sarcoma, Interdigitating 1 Congenital Abnormalities 1

Interventions

Rituximab 15 Peripheral Blood Stem Cell Transplantation 13 Cyclophosphamide 12 fludarabine phosphate 11 Whole-Body Irradiation 9 Cyclosporine 9 Mycophenolic Acid 8 Filgrastim 8 Methotrexate 7 Lenalidomide 7 Etoposide 7 Tacrolimus 5 Radiotherapy 5 Dexamethasone 5 Cytarabine 5 Vorinostat 4 Therapeutics 4 Psychiatric Rehabilitation 4 Melphalan 4 Carboplatin 4 Antilymphocyte Serum 4 Thiotepa 3 Irinotecan 3 Granulocyte Colony-Stimulating Factor 3 Flow Cytometry 3 Dasatinib 3 Busulfan 3 Bortezomib 3 tanespimycin 2 pegfilgrastim 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06973811 2025-05-20

ZR-MTX

Peking Union Medical College Hospital

Phase 2 Not yet recruiting

Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡